Side-by-side · Research reference

RetatrutidevsTriptorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED10/41 cited

BFDA-ApprovedHUMAN-REVIEWED16/64 cited

Retatrutide

Triple-receptor agonist · Phase 3

1–12 mgWeekly doseJastreboff 2023

24.2%Body-weight ↓Jastreboff 2023

~6 daysHalf-life (est)

SQ · Abdomen · Once weekly

Triptorelin

GnRH Agonist · FDA-Approved

3.75–22.5 mgDepot dose rangeYee 2025 Chen 2024

<50 ng/dLTestosterone target

1–6 monthsDepot durationYee 2025 Chen 2024

IM · Depot Injection · Monthly to 6-MonthlyYee 2025

01Mechanism of Action

Parameter

Retatrutide

Triptorelin

Primary target

GLP-1R + GIPR + Glucagon receptor (triple agonism)Jastreboff 2023

Pituitary GnRH receptorsUnknown 2012

Pathway

Triple-receptor activation → ↑insulin (GLP-1+GIP), ↓gastric emptying, ↑lipid handling, ↑energy expenditure (glucagon component)Jastreboff 2023

GnRH receptor agonism → initial flare (LH/FSH spike) → receptor desensitization → sustained LH/FSH suppression

Downstream effect

Maximal weight loss across class. Glucagon component drives lipolysis and energy expenditure beyond GLP-1+GIP aloneJastreboff 2023

Castration-level suppression of testosterone (men) and estrogen (women) within 2–4 weeks post-flare

Feedback intact?

—

No — bypasses physiological pulsatility; continuous agonism produces paradoxical suppression

Origin

Synthetic peptide engineered for balanced affinity at three incretin / glucagon receptorsJastreboff 2023

Synthetic decapeptide analogue of native GnRH with amino acid substitutions for enhanced receptor affinity and stability

Antibody development

—

02Dosage Protocols

Parameter

Retatrutide

Triptorelin

Standard dose

12 mg / week (max efficacy)Jastreboff 2023

Phase 2 trial dose. Phase 3 dosing TBD.

—

Frequency

Once weekly

Every 1, 3, or 6 months per formulation

Titration schedule

2 mg → 4 mg → 8 mg → 12 mg over 16 weeks

—

Evidence basis

Phase 2 trial; Phase 3 ongoingJastreboff 2023

Multiple Phase 3 RCTs · FDA-approved 1999

Duration

Indefinite for chronic indication (presumed)

—

Reconstitution

Investigational; not commercially available

—

Timing

Any time of day

—

Half-life

~6 days (estimated from class)

—

1-month depot

—

3.75 mg IM

Most common formulation for prostate cancer.

3-month depot

—

11.25 mg IMYee 2025

Reduced injection frequency.

6-month depot

—

22.5 mg IMYee 2025 Chen 2024

Long-acting formulation; improved adherence in real-world use.Yee 2025

Administration route

—

Intramuscular (IM) — gluteal or deltoid

Indication: Prostate cancer

—

Advanced (metastatic or locally advanced)

Androgen deprivation therapy (ADT) backbone.

Indication: Endometriosis

—

3.75 mg monthly

FDA-approved; typically 6-month course.

Indication: Central precocious puberty

—

Pediatric use (≥2 years)Jia 2025

Weight-based dosing per FDA label.

Duration (prostate cancer)

—

Continuous or intermittent ADT protocolsPreston 2024

Intermittent ADT may reduce side effects; cardiovascular risk similar to continuous.

Monitoring

—

Serum testosterone, PSA (prostate cancer), bone density, lipids, glucose

04Side Effects & Safety

Parameter

Retatrutide

Triptorelin

GI symptoms

Nausea, vomiting, diarrhea (very common, dose-dependent)Jastreboff 2023

—

Heart rate

↑ resting HR (3–7 bpm at 12 mg)Jastreboff 2023

—

Glucose handling

Glycemic improvement; rare hyperglycemia from glucagon component

—

Pancreatitis risk

Class warning

—

Thyroid C-cell tumours

Class warning (presumed)

—

Pregnancy / OB

Avoid (insufficient data)

—

Initial flare symptoms

—

Bone pain, urinary obstruction, spinal cord compression (first 2 weeks)

Antiandrogen co-treatment (bicalutamide) mitigates flare in metastatic disease.

Cardiovascular events

—

MI, stroke, arrhythmia — GnRH agonists show higher CV risk vs antagonists in meta-analysesPatel 2025 Preston 2024

Hot flashes

—

Very common (>60%); vasomotor instability

Bone loss / Osteoporosis

—

Accelerated bone mineral density decline; fracture risk ↑Friedrich 2025

Baseline DEXA scan recommended; bisphosphonates or denosumab may be indicated.

Metabolic syndrome

—

Weight gain, insulin resistance, dyslipidemia, diabetes risk

Sexual dysfunction

—

Erectile dysfunction, loss of libido (expected pharmacological effect)Jia 2025

Injection site reactions

—

Pain, erythema, sterile abscess (rare with depot formulations)

Gynecomastia / Breast tenderness

—

Common (10–20%); peripheral aromatization of residual androgens

Fatigue / Mood changes

—

Anemia, depression, cognitive changes reported in long-term ADT

Hepatotoxicity

—

Transient transaminase elevations; clinically apparent liver injury rare

Racial differences (ADT)

—

Black veterans show higher CV event rates vs White veterans on GnRH agonists

Absolute Contraindications

Retatrutide

·MTC personal or family history (presumed class effect)
·Pregnancy / breastfeeding

Triptorelin

·Hypersensitivity to triptorelin, GnRH, or GnRH agonist analogues
·Pregnancy (Category X)

Relative Contraindications

Retatrutide

·Severe gastroparesis
·History of pancreatitis
·Severe cardiovascular disease (HR signal)

Triptorelin

·Active cardiovascular disease — consider GnRH antagonist alternative
·Metastatic vertebral disease with spinal cord compression risk (flare hazard)
·Severe urinary obstruction — may worsen during flare
·Osteoporosis or high fracture risk (requires bone-protective therapy)

05Administration Protocol

Parameter

Retatrutide

Triptorelin

1. Reconstitution

Investigational peptide. Research vials reconstituted with bacteriostatic water per label.

Choose 1-month (3.75 mg), 3-month (11.25 mg), or 6-month (22.5 mg) depot based on adherence needs and clinical context. 6-month formulation shows improved real-world adherence in Asia-Pacific cohorts.

2. Injection site

SQ — abdomen, thigh, or upper arm. Rotate weekly.

Intramuscular — gluteal or deltoid muscle. Use 21–23G needle. Aspirate to confirm non-vascular placement. Rotate sites with repeat injections.

3. Timing

Once weekly, same day.

For metastatic prostate cancer: co-administer antiandrogen (e.g., bicalutamide 50 mg daily) starting 1 week before first injection and continuing 2–4 weeks to prevent tumor flare.

4. Storage

Refrigerate 2–8 °C. Light-protected.

Baseline: testosterone, PSA, bone density (DEXA), lipids, glucose. Follow-up: testosterone at 4 weeks (confirm <50 ng/dL castration), PSA monthly × 3, then quarterly. Annual DEXA for bone loss.

5. Needle

27–31G, 4–8 mm insulin syringe.

Store vials at room temperature (20–25 °C), protect from light. Do not freeze. Reconstituted suspension should be used immediately.

6. Intermittent ADT protocol (optional)

—

Some protocols use on-treatment periods (9–12 months) alternating with off-treatment intervals until PSA rises. Cardiovascular risk appears similar to continuous ADT.